LIGAND PHARMACEUTICALS INC Insider Trading for February 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for February 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 107.58 | 7,000 | 753,060 | 153,898 | 160.9 K to 153.9 K (-4.35 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 106.00 | 25,000 | 2,650,000 | 160,898 | 185.9 K to 160.9 K (-13.45 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 100.38 | 9,643 | 967,964 | 9,643 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 2,259 | 0 | 42,805 | 40.5 K to 42.8 K (+5.57 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 2,619 | 0 | 40,546 | 37.9 K to 40.5 K (+6.91 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 100.38 | 15,225 | 1,528,286 | 15,225 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,567 | 0 | 15,072 | 11.5 K to 15.1 K (+31.00 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 100.38 | 1,051 | 105,499 | 11,505 | 12.6 K to 11.5 K (-8.37 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,450 | 0 | 12,556 | 9.1 K to 12.6 K (+37.89 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 104.28 | 391 | 40,773 | 9,106 | 9.5 K to 9.1 K (-4.12 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 123.30 | 609 | 75,090 | 9,457 | 10.1 K to 9.5 K (-6.05 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 100.38 | 25,376 | 2,547,243 | 25,376 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 7,544 | 0 | 90,720 | 83.2 K to 90.7 K (+9.07 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 100.38 | 2,733 | 274,339 | 83,176 | 85.9 K to 83.2 K (-3.18 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 5,239 | 0 | 85,909 | 80.7 K to 85.9 K (+6.49 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 104.28 | 725 | 75,603 | 80,670 | 81.4 K to 80.7 K (-0.89 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 104.28 | 1,642 | 171,228 | 81,395 | 83 K to 81.4 K (-1.98 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 100.38 | 43,646 | 4,381,185 | 43,646 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 10,224 | 0 | 132,969 | 122.7 K to 133 K (+8.33 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 100.38 | 4,783 | 480,118 | 122,745 | 127.5 K to 122.7 K (-3.75 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,168 | 0 | 127,528 | 118.4 K to 127.5 K (+7.75 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 104.28 | 2,019 | 210,541 | 118,360 | 120.4 K to 118.4 K (-1.68 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 104.28 | 2,285 | 238,280 | 120,379 | 122.7 K to 120.4 K (-1.86 %) |